Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of XW003 injection in obesity-associated obstructive sleep apnea without PAP treatment
CTR20260254Phase 3Active
- Sponsor
- Sciwind Biosciences
- Start
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of ecnoglutide in obstructive sleep apnea hypopnea syndrome (OSAHS), obesity, sponsored by Sciwind Biosciences. Started Feb 2026; status: active.
02
Drugs
ecnoglutide
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)obesity
Beyond the preview
Go deeper on CTR20260254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260254.